Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Feb
23
Today In Oncology
Multiple Myeloma FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
New Biomarker May Predict Chemotherapy Response in Patients With Triple-Negative Breast Cancer
Acral Melanoma Ancestry and Genetics Impact Outcomes
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo